CAR T Cells in Mesothelin-Expressing Breast Cancer
Phase 1, Adaptive-design Trial of Human Chimeric Antigen Receptor Modified T Cells in Patients With Mesothelin Expressing Breast Cancer
Sponsor: University of Pennsylvania
Terminated
Feasibility Concerns
Other terminated trials from University of Pennsylvania
This PHASE1 trial investigates Breast Cancer and is currently terminated or withdrawn. University of Pennsylvania leads this study, which shows 12 recorded versions since 2023 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
12 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE1
-
Jul 2025 — Sep 2025 [monthly]
Terminated PHASE1
-
Jun 2025 — Jul 2025 [monthly]
Terminated PHASE1
Status: Active Not Recruiting → Terminated
-
Apr 2025 — Jun 2025 [monthly]
Active Not Recruiting PHASE1
Status: Recruiting → Active Not Recruiting
-
Feb 2025 — Apr 2025 [monthly]
Recruiting PHASE1
▶ Show 7 earlier versions
-
Sep 2024 — Feb 2025 [monthly]
Recruiting PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE1
-
Feb 2024 — Jul 2024 [monthly]
Recruiting PHASE1
-
Jul 2023 — Feb 2024 [monthly]
Recruiting PHASE1
-
Mar 2023 — Jul 2023 [monthly]
Recruiting PHASE1
Status: Not Yet Recruiting → Recruiting
-
Feb 2023 — Mar 2023 [monthly]
Not Yet Recruiting PHASE1
-
Dec 2022 — Feb 2023 [monthly]
Not Yet Recruiting PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- University of Pennsylvania
For direct contact, visit the study record on ClinicalTrials.gov .